Browse the evidence

Mendelian randomisation did not find evidence that genetically proxied GLP-1RA increased suicide attempts in a general population cohort.

There is no genetic evidence to support an association between GLP-1RA and increased suicide attempts, suggesting safety in this regard.

There is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.

Clinicians should be cautious and consider FDA approval status when prescribing incretin analogs.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Approximately 10% of obesity-related glomerulopathy (ORG) patients progress to end stage renal disease 6.2 years after diagnosis.

Healthcare providers should monitor ORG patients closely for progression to end stage renal disease.

The pathogenesis of obesity-related glomerulopathy is complex, involving multiple factors.

Recognizing the complexity of ORG can guide more targeted therapeutic approaches.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Amylin and salmon calcitonin target distinct neurons in various brain regions.

Insights into neural targeting can inform obesity treatment strategies.

The internet-based marketing of plant-based formulations for enhancing metabolism has surged.

Practitioners should be aware of the growing trend in plant-based metabolism enhancers in the market.

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.

Differences between the groups regarding the primary outcome (composite score of physical functioning) could not be identified due to early termination.

Early termination of studies can limit the ability to draw conclusions about treatment effects.

The use of GLP-1RA medications has been associated with increased hypoglycaemia risk in patients treated with concomitant antihyperglycaemic medications.

Clinicians should monitor for hypoglycaemia when initiating GLP-1RA therapy in patients on other antihyperglycaemic medications.

Identifying molecular targets for inducing muscle remodeling could provide new approaches to treat metabolic syndrome.

Targeting specific molecular pathways may enhance treatment options for metabolic syndrome patients.

GIP(1-30)NH2 and GIP(1-42) have similar effects on human pancreatic islets.

Both GIP variants can be expected to have similar effects on insulin and glucagon secretion in pancreatic islets.

There were no significant between-group differences in VAT volume after 6 months or 12 months.

Dietary interventions may not differ significantly in their effects on VAT volume over time.

Statins have not mitigated the incidence or prevalence of cardiovascular disease (CVD).

Practitioners should reconsider the reliance on statins for CVD prevention.

The SDOC definition has high discriminatory accuracy for identifying ADL disability.

The SDOC criteria can be effectively used to assess risk of ADL disability in older adults.

Demographics associated with higher prescription period prevalence included non-Hispanic Black race and ethnicity, female sex, and older age.

Understanding these demographic factors can help tailor interventions and support for specific groups.

Semaglutide is available in two formulations: once-weekly subcutaneous and once-daily oral.

Practitioners can offer patients a choice between two formulations of semaglutide for weight management.

There was no significant difference in weight loss between the intervention and control groups at 6 months (P=0.26).

Inpatient obesity interventions with postdischarge follow-up may not lead to significant weight loss.

There were no differences in waist-to-hip ratios between the intervention and control at 6 months.

The intervention did not affect waist-to-hip ratios, indicating no change in body composition.

The ten largest food companies in the United States control over half of all food sales.

Practitioners should be aware of the significant market power held by a few companies in the food industry.

Worldwide, the largest food companies control about 15% of food sales, and this proportion is rising.

Practitioners should consider the increasing influence of major companies on global food systems.

More than half of global soft drinks are produced by large multinational companies, mainly Coca-Cola and PepsiCo.

Practitioners should recognize the significant market share held by major soft drink companies.